Trimetazidine protective effect against ischemia-induced susceptibility to ventricular fibrillation in pigs

Cardiovascular Drugs and Therapy

Volumn 22, Issue 1, 2008, Pages 29-36

  Vaillant, Fanny ^a   Tsibiribi, Panayota ^a   Bricca, Giampiero ^a   Bui Xuan, Bernard ^a   Bescond Jacquet, Anne ^b   Tabib, Alain ^c   Descotes, Jacques ^d   Timour, Quadiri ^a,d  

^a UNIVERSITÉ LYON 1   (France)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d Centre Antipoison Centre de Pharmacovigilance   (France)

Author keywords

Myocardial ischemia; Pig; Trimetazidine; Ventricular fibrillation

Indexed keywords

MALONALDEHYDE; PLACEBO; TRIMETAZIDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE PREDISPOSITION; DRUG EFFECT; ELECTROCARDIOGRAM; ELECTROSTIMULATION; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART RATE; HEART VENTRICLE FIBRILLATION; HEMODYNAMIC PARAMETERS; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LIPID PEROXIDATION; MALE; NONHUMAN; PRIORITY JOURNAL; SWINE; SYSTOLIC BLOOD PRESSURE; THORACOTOMY;

ANIMALS; CORONARY VESSELS; DISEASE MODELS, ANIMAL; ELECTRIC STIMULATION; FEMALE; HEART RATE; HOMEOSTASIS; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; MYOCARDIAL ISCHEMIA; SWINE; TRIMETAZIDINE; VASODILATOR AGENTS; VENTRICULAR FIBRILLATION;

EID: 39149116316     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-007-6076-5     Document Type: Article

References (49)

1. Janse MJ, Wit AL. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol Rev. 1989;69:1049-169.
2. Roelandt J, Klootwijk P, Lubsen J, Janse MJ. Sudden death during long-term ambulatory monitoring. Eur Heart J. 1984;5:7-20.
3. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Mortality and morbidity in patients receiving encainide, flecainide or placebo. N Engl J Med. 1991;324:781-8.
4. Aupetit JF, Loufoua-Moundanga J, Faucon G, Timour Q. Ischaemia-induced loss or reversal of the effects of the class I antiarrhythmic drugs on vulnerability to fibrillation. Br J Pharmacol. 1997;120:523-9.
5. Timour Q, Bui-Xuan B, Aupetit JF, Freysz M, Evreux JC, Faucon G. Calcium antagonists and prevention of ventricular fibrillation induced by transient or persistent ischemia. Jpn Heart J. 1997;38:237-51.
6. Pantos C, Bescond-Jacquet A, Tzeis S, Paizis I, Mourouzis I, Moraïtis P, et al. Trimetazidine protects isolated rat hearts against ischemia-reperfusion in an experimental timing-dependant manner. Basic Res Cardiol. 2005;100:154-60.
7. Szwed H, Sadowski Z, Elikowski W, Koronkiewicz A, Mamcarz A, Orszulak W, et al. Combination treatment in stable effort angina using trimetazidine and metoprolol. Results of a randomised, double-blind, multicentre study (TRIMPOL II). Eur Heart J. 2001;22:2267-74.
8. Sellier P, Broustet JP. Assessment of anti-ischemic and antianginal effect at trough plasma concentration and safety of trimetazidine MR 35 mg in patients with stable angina pectoris: a multicenter, double-blind, placebo-controlled study. Am J Cardiovasc Drugs. 2003;3:361-9.
9. Marzilli M, Klein WW. Efficacy and tolerability of trimetazidine in stable angina: a meta-analysis of randomized, double-blind, controlled trials. Coron Artery Dis. 2003;14:171-9.
10. Kantor PF, Lucien A, Kozak R, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2000;86:487-9.
11. Sentex E, Sergiel JP, Lucien A, Grynberg A. Trimetazidine increased phospholipid turnover in ventricular myocytes. Mol Cell Biochem. 1997;175:153-62.
12. Lopaschuk GD, Barr R, Thomas PD, Dyck JR. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase. Circ Res. 2003;93:33-7.
13. Guarnieri C, Muscari C. Effect of trimetazidine on mitochondrial function and oxidative damage during reperfusion of ischaemic hypertrophied rat myocardium. Pharmacology 1993;46:324-31.
14. Kara AF, Demiryurek S, Celik A, Tarakcioglu M, Demiryurek AT. Effects of trimetazidine on myocardial preconditioning in anesthetized rats. Eur J Pharmacol. 2004;503:135-45.
15. Yagi K. A simple fluorimetric assay for lipoperoxides in blood plasma. Biochem Res. 1976;15:212-6.
16. Nachlas MM, Shnitka TK. Macroscopic identification of early myocardial infarcts by alteration in dehydrogenase activity. Am J Pathol. 1963;42:379-83.
17. Feola M, Biggi A, Francini A, et al. Trimetazidine improves myocardial perfusion and left ventricular function in ischemic left ventricular dysfunction. Clin Nucl Med. 2004;29:117-8.
18. Dalla-Volta S, Maraglino G, Della-Valentina P, Viena P, Desideri A. Comparison of trimetazidine with nifedipine in effort angina. A double-blind, crossover study. Cardiovasc Drugs Ther. 1990;4:853-60.
19. Detry JM, Sellier P, Pennaforte S, Cokkinos D, Dargie H, Mathes P. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Br J Clin Pharmacol. 1994;37:279-88.
20. Szwed H. Clinical benefits of trimetazidine in patients with recurrent angina. Coron Artery Dis. 15 2004;Suppl 1:S17-21.
21. Emre M, Karayaylali I, San M, Demirkazik A, Kavak S. The acute effect of trimetazidine on the high frequency fatigue in the isolated rat diaphragm muscle. Arch Pharm Res. 2004;27:646-52.
22. Lazzarino G, Tavazzi B, Di Pierro D, Vagnozzi R, Penco M, Giardina B. The relevance of malondialdehyde as a biochemical index of lipid peroxidation of postischemic tissues in the rat and human beings. Biol Trace Elem Res. 1995;47:165-70.
23. Mateos R, Lecumberri E, Ramos S, Goya L, Bravo L. Determination of malondialdehyde (MDA) by high-performance liquid chromatography in serum and liver as a biomarker for oxidative stress. Application to a rat model for hypercholesterolemia and evaluation of the effect of diets rich in phenolic antioxidants from fruits. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;827:76-82.
24. Monteiro P, Duarte AI, Goncalves LM, Moreno A, Providencia LA. Protective effect of trimetazidine on myocardial mitochondrial function in an ex-vivo model of global myocardial ischemia. Eur J Pharmacol. 2004;503:123-8.
25. Koning MMG, Krams R, Xiao CS, van Meegen JR, Bezstarosti K, Lamers JMJ, Verdouw PD. Intracoronary trimetazidine does not improve recovery of regional function in a porcine model of repeated ischemia. Cardiovasc Drugs Ther. 1993;7:801-7.
26. Roberts MJ, Young IS, Trouton TG, Trimble ER, Khan MM, Webb SW, Wilson CM, Patterson GC, Adgey AA. Transient release of lipid peroxides after coronary artery balloon angioplasty. Lancet. 1990;336:143-5.
27. Kioueh I, Mosnier M, Bui-Xuan B, Frassati D, Descotes J, Timour Q. [Deleterious cardiac effects of serotonin in myocardial ischemia: role of naftidrofuryl]. Ann Cardiol Angeiol (Paris). 2001;50:229-38.
28. 2+ overload in reperfused ischemic myocardium. Annu Rev Physiol. 1990;52:543-59.
29. Gettes LS, Cascio WE, Johnson T, Fleet WF. Local myocardial biochemical and ionic alterations during myocardial ischaemia and reperfusion. Drugs. 1991;42:7-13.
30. Clusin WT, Bristow MR, Karagueuzian HS, Katzung BG, Schroeder JS. Do calcium-dependent ionic currents mediate ischemic ventricular fibrillation? Am J Cardiol. 1982;49:606-12.
31. Coetzee WA, Enous R, Opie LH. Trimetazidine: effects on delayed afterdepolarizations (DADs) and upstroke velocity of the action potential. Cardiovasc Drugs Ther. 1990;4:806-7.
32. Kiyosue T, Nakamura S, Arita M. Effects of trimetazidine on action potentials and membrane currents of guinea-pig ventricular myocytes. J Mol Cell Cardiol. 1986;18:1301-11.
33. Timour Q, Bui-Xuan B, Faucon G, Aupetit JF. Delay by a calcium antagonist, amlodipine, of the onset of primary ventricular fibrillation in myocardial ischemia. Cardiovasc Drugs Ther. 1996;10:447-54.
34. Timour Q, Aupetit JF, Freysz M, Frassati D, Faucon G. Possible prevention by amlodipine of ventricular fibrillation related to brief ischemia episodes. Can J Physiol Pharmacol. 1996a;74:1308-14.
35. Timour Q, Larbre JP, Kioueh I, Aupetit JF, Loufoua-Moundanga J, Vialle A, Faucon G. Calcium channel modulators and susceptibility to ischaemic ventricular fibrillation: modification of cellular calcium overload. Arch Int Pharmacodyn Ther. 1992;315:30-46.
36. El Banani H, Bernard M, Baetz D, et al. Changes in intracellular sodium and pH during ischaemia-reperfusion are attenuated by trimetazidine. Comparison between low- and zero-flow ischaemia. Cardiovasc Res. 2000;47:688-96.
37. + during myocardial ischemia: consequences for post-ischemic recovery. J Mol Cell Cardiol. 1997;29:85-96.
38. + exchange are immediately active upon post-ischaemic reperfusion in isolated rat hearts. J Mol Cell Cardiol. 1998;30:337-48.
39. 2+ regulation by trimetazidine during cardiac cell acidosis. Cardiovasc Drugs Ther. 1988;1:677-86.
40. Lee L, Horowitz J, Frenneaux M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J. 2004;25:634-41.
41. Belardinelli L, Antzelevitch C, Fraser H. Inhibition of late (sustained/persistent) sodium current: a potential target to reduce intracellular sodium-dependent calcium overload and its detrimental effects on cardiomyocyte function. Eur Heart J. 2004;6:3-7.
42. Stanley WC. Myocardial energy metabolism during ischemia and the mechanisms of metabolic therapies. J Cardiovasc Pharmacol Ther. 2004;9:S31-45.
43. Kudo N, Barr AJ, Barr RL, Desai S, Lopaschuk GD. High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5′-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J Biol Chem. 1995;270:17513-20.
44. Wolff AA, Rotmensch HH, Stanley WC, et al. Metabolic approaches to the treatment of ischemic heart disease: the clinicians' perspective. Heart Fail Rev. 2002;7:187-203.
45. Argaud L, Ovize M. Myocardial metabolism abnormalities during ischemia and reperfusion. Arch Mal Coeur Vaiss. 2000;93:87-90.
46. MacInnes A, Fairman DA, Binding P, Rhodes J, Wyatt MJ, Phelan A, Haddock PS, Karran EH. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2003;93:26-32.
47. Lopaschuk GD, Belke DD, Gamble J, Itoi I, Schönekess BO. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta. 1994;1213:263-76.
48. Stanley WC, Lopaschuk GD, Hall JL, McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischemic conditions: potential for pharmacological interventions. Cardiovasc Res. 1997;33:243-57.
49. Liu B, Clanachan AS, Schulz R, Lopaschuk GD. Cardiac efficiency is improved after ischemia by altering both the source and fate of protons. Circ Res. 1996;79:940-8.